Description: Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies. Pure Biologics Spólka Akcyjna was incorporated in 2010 and is headquartered in Wroclaw, Poland.
Home Page: purebiologics.com
ul. Dunska 11
Wroclaw,
54-427
Poland
Phone:
48 795 61 18 11
Officers
| Name | Title |
|---|---|
| Dr. Filip Jelen M.B.A., Ph.D. | Co-founder & Pres of the Management Board |
| Mr. Romuald Apollo Harwas | VP of the Management Board & CFO |
| Dr. Pieter Spee | VP of the Management Board & CSO |
| Ms. Marta Wawrzyniak M.B.A. | Chief Operating Officer |
| Mr. Maciej Mazurek M.B.A. | Director of Science & Innovation |
| Ms. Aldona Pietraszek | Head of the Admin. |
| Ms. Martyna Koj | Director of the Company Office & Investor Relations Representative |
| Ms. Marta Rot | Head of HR |
| Dr. Michal Pirog | Head of the Laboratory |
| Mr. Przemyslaw Dudek | Head of Information Technology |
Exchange: WAR
Country: PL
Currency: Polish złoty (zł)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5277 |
| Price-to-Sales TTM: | 106.481 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 101 |